Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients

Skin Pharmacology and Physiology

Volumn 18, Issue 6, 2005, Pages 273-278

  Borelli, C ^a   Kunte, C ^a   Weisenseel, P ^a   Thoma Greber, E ^a   Korting, H C ^a   Konz, B ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Filler; Highly active antiretroviral therapy; HIV infection; Lipoatrophy; Poly L lactic acid

Indexed keywords

POLYLACTIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MALE; PILOT STUDY; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; TREATMENT OUTCOME;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOCOMPATIBLE MATERIALS; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMERS; SKINFOLD THICKNESS;

EID: 27344460619     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087608     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Buffet M, Schwarzinger M, Amellal B, Gourlain K, Bui P, Prevot M, Deleuze J, Morini J, Gorin I, Calvez V, Dupin N: Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol 2005;33:60-64.
3. Nolan D, Mallal S: The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. J HIV Ther 2004;9:34-40.
4. Carr A: HIV lipodystrophy : risk factors, pathogenesis, diagnosis and management. AIDS 2003;17(suppl 1):141-148.
5. Moyle G, Sutinen J: Managing HIV lipoatrophy. Lancet 2004;363:412-414.
6. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell JM: Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-598.
7. McComsey G, Maa JF: Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003;13:539-542, 559.
8. Villarroya F, Domingo P, Giralt M: Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: The adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005;26:88-93.
9. James J, Carruthers A, Carruthers J: HIV-associated facial lipoatrophy. Dermatol Surg 2002;28:979-986.
10. Bomhovd E, Sakrauski AK, Bruhl H, Walli R, Plewig G, Rocken M: Multiple circumscribed subcutaneous lipomas associated with use of human immunodeficiency virus protease inhibitors? Br J Dermatol 2000;143:1113-1114.
11. Mallon PW, Wand H, Law M, Miller J, Cooper DA, Carr A: Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. J Acquir Immune Defic Syndr 2005;38:156-162.
12. Carr A: Cardiovascular risk factors in HIV-infected patients. J Acquir Immune Defic Syndr 2003;34(suppl 1):73-78.
13. Group EPL: Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-1451.
14. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
15. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
16. Cofrancesco J Jr, Brown T, Martins CR: Management options for facial lipoatrophy. AIDS Read 2004;14:639-640, 645-650.
17. Hansen BR, Haugaard SB, Iversen J, Nielsen JO, Andersen O: Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis 2004;36:244-253.
18. Anonymous: FDA approves lipoatrophy filler. AIDS Patient Care STDs 2004;18:366.
19. Dermik Laboratories: New-Fill skin implant. Prescribing information, 2003.
20. Woerle B, Hanke CW, Sattler G: Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 2004;3:385-389.
21. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, Bousquet R, Katz P, Costagliola D, Katlama C: Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003;17:2471-2477.
22. Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, Mandalia S, Barton SE: A randomized open-label study of immediate versus delayed poly lactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004;5:82-87.
23. Perry CM: Poly-L-lactic acid. Am J Clin Dermatol 2004;5:361-366; discussion 367-368.
24. Eppley BL, Reilly M: Degradation characteristics of PLLA-PGA bone fixation devices. J Craniofac Surg 1997:116-120.
25. Schurig V, Konz B, Ring J, Dorn M: Granulombildung an Test- und Behandlungsstellen durch intrakutan verabreichtes, injizierbares Kollagen. Hautarzt 1986;37:42-45.
26. Borelli C, Korting HV: Poly-L-lactic acid: a viewpoint by Claudia Borelli and Hans Christian Korting. Am J Clin Dermatol 2004;5:367-368.
27. Oppel T, Schaller M, Flaig M, Korting HC: Fremdkörpergranulome nach dermaler Injektion eines auf Polymilchsäure basierenden Implantates zur Behandlung von Falten. JDDG 2003;1:220-222.
28. Sculptra (injectable poly-L-lactic acid) Product information, Dermik Laboratories, 2004.
29. Boix V: Polylactic acid implants. A new smile for lipoatrophic faces? AIDS 2003;17:2533-2535.